journal article·2026-07

Hypoxia-responsive photosensitizer prodrug for bimodal chemo-photodynamic therapy

Ao-Jun Qiu, Chun-Hui Qiu, Xin-Yu Xia, Fenying Wang, Qian-Yong Cao

Dyes and Pigments· Volume 250
Publisher page

Abstract

The tumor hypoxic environment and photodynamic therapy (PDT) induced hypoxia could severely limit the therapeutic efficacy of traditional PDT. The integration of hypoxia-responsive prodrug with photosensitizer (PS) might solve this problem in the hypoxic environment of solid tumors. Here in we design and synthesize a novel prodrug functionalized PS TPA-Py-NM, in which the AIE-based PS and nitrogen mustard (NM), a chemotherapy drug, were linked by the hypoxia-responsive azo linker. TPA-Py-NM exhibits AIE-based red emission at 726 nm, and produces 1O2 (type II ROS) and O2•– (type I ROS) under white light irritation. In hypoxic tumors, the azo group of TPA-Py-NM was reduced to no fluorescent aniline derivative and drug NM, which enhance cancer cells killing efficiency both in light or darkness for synergistic PDT and chemotherapy effect. In contrast, the control PS TPA-Py-DM without NM components exhibited weaker cancer cell killing ability under hypoxic conditions.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (39)

Show source-provided references
1. Flavonoids nanoparticles in cancer: treatment, prevention and clinical prospects10.1016/j.semcancer.2019.07.023 ↗
2. Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis10.1016/j.jconrel.2022.10.023 ↗
3. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications10.1016/j.jconrel.2014.12.030 ↗
4. Photochemistry and non-adiabatic photodynamics of the HOSO radical10.1021/jacs.1c05149 ↗
5. Focal photodynamic intracellular acidification as a cancer therapeutic10.1016/j.semcancer.2017.02.005 ↗
6. Photodynamic and photothermal therapies: synergy opportunities for nanomedicine10.1021/acsnano.3c00891 ↗
7. Photophysics and photochemistry of photodynamic therapy: fundamental aspects10.1007/s10103-008-0539-1 ↗
8. Bridging D–A type photosensitizers with the azo group to boost intersystem crossing for efficient photodynamic therapy10.1039/D2SC00381C ↗
9. Activatable phototherapeutic prodrug conquering hypoxia limitation to enhance chemical drug delivery efficiency10.1021/acsmaterialslett.4c00750 ↗
10. Light-enhanced hypoxia-response of conjugated polymer nanocarrier for successive synergistic photodynamic and chemo-therapy10.1021/acsami.8b06491 ↗
11. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy10.1038/ncomms9785 ↗
12. Biodegradable biomimic copper/manganese silicate nanospheres for chemodynamic/photodynamic synergistic therapy with simultaneous glutathione depletion and hypoxia relief10.1021/acsnano.8b09387 ↗
13. Dual‐stage light amplified photodynamic therapy against hypoxic tumor based on an O2 self‐sufficient nanoplatform10.1002/smll.201701621 ↗
14. Integration of an AIE photosensitizer and a COX-2 inhibitor for synergistic and enhanced tumor therapy10.1016/j.bioorg.2025.108891 ↗
15. Biomimetic upconversion nanoplatform synergizes photodynamic therapy and enhanced radiotherapy against tumor metastasis10.1021/acsami.3c03636 ↗
16. Synergistic comprehensive activation methods for dual‐modality PDT and hypoxia‐triggered chemotherapy guided by NIR‐II imaging beyond 1700 nm in deep tumors10.1002/smll.202500553 ↗
17. Targeted pH-Activated peptide-based nanomaterials for combined photodynamic therapy with immunotherapy10.1021/acs.biomac.4c00141 ↗
18. Photodynamic therapy-improved oncolytic bacterial immunotherapy with FAP-Encoding S. typhimurium10.1016/j.jconrel.2022.09.050 ↗
19. Tuning organelle specificity and photodynamic therapy efficiency by molecular function design10.1021/acsnano.9b04430 ↗
20. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review10.1016/j.biomaterials.2016.01.061 ↗
21. Stimuli-responsive liposomal nanoformulations in cancer therapy: pre-clinical & clinical approaches10.1016/j.jconrel.2022.08.001 ↗
22. Molecular mechanisms of ATP secretion during immunogenic cell death10.1038/cdd.2013.75 ↗
23. The microenvironment of the tumour–host interface10.1038/35077241 ↗
24. Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics10.1016/j.addr.2021.113907 ↗
25. Two-dimensional nanomaterials for tumor microenvironment modulation and anticancer therapy10.1016/j.addr.2022.114360 ↗
26. Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment10.1016/j.addr.2021.114004 ↗
27. Designing a hypoxia-activated sensing platform using an azo group-triggered reaction with the formation of silicon nanoparticles10.1021/acs.analchem.4c01857 ↗
28. Hypoxia and singlet oxygen dual-responsive micelles for photodynamic and chemotherapy therapy featured with enhanced cellular uptake and triggered cargo delivery10.2147/IJN.S432407 ↗
29. PEGylated AIEgen molecular probe for hypoxia-mediated tumor imaging and photodynamic therapy10.1039/D1CC00967B ↗
30. Totally caged type I pro‐photosensitizer for oxygen‐independent synergistic phototherapy of hypoxic tumors10.1002/advs.202400462 ↗
31. The design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy10.1039/D2CS00673A ↗
32. Emerging combination strategies with phototherapy in cancer nanomedicine10.1039/D0CS00215A ↗
33. Synergistic cancer treatment strategies using platinum-porphyrin conjugates10.1016/j.ccr.2025.216873 ↗
34. Synergistic effects of combining phototherapeutics with traditional treatment modalities in oncology10.1039/D5CC02816G ↗
35. Advances in photodynamic therapy and its combination strategies for breast cancer10.1016/j.actbio.2025.08.054 ↗
36. Functional upgrading of an Organo–Ir(III) complex to an Organo–Ir(III) prodrug as a DNA damage-responsive autophagic inducer for hypoxic lung cancer therapy10.1021/acs.inorgchem.4c00060 ↗
37. AIE donor-dependent photosensitizer for enhance photodynamic antibacterial interface
38. Molecular design toward heavy-atom-free photosensitizers based on the C═S bond and their dual functions in hypoxia photodynamic cancer therapy and ClO– detection10.1021/acsami.0c22174 ↗
39. Hypoxia-responsive polymeric nanoprodrugs for combo photodynamic and chemotherapy10.1021/acsomega.3c08504 ↗